Technical Analysis for CRBU - Caribou Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Bullish Engulfing | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 7.67% | |
| Lower Bollinger Band Walk | Weakness | 7.67% | |
| New 52 Week Low | Weakness | 7.67% | |
| Wide Bands | Range Expansion | 7.67% | |
| Below Lower BB | Weakness | 7.67% | |
| Down 3 Days in a Row | Weakness | 7.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 1 ATR | about 11 hours ago |
| Rose Above Previous Day's High | about 14 hours ago |
| Up 5% | about 14 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/20/2023
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Hematologic Malignancies Breakthrough Therapy Chimeric Antigen Receptor T Cell CD19 Refractory Acute Myeloid Leukemia T Cells Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.19 |
| 52 Week Low | 4.12 |
| Average Volume | 450,939 |
| 200-Day Moving Average | 8.07 |
| 50-Day Moving Average | 6.26 |
| 20-Day Moving Average | 5.35 |
| 10-Day Moving Average | 4.87 |
| Average True Range | 0.35 |
| RSI | 31.03 |
| ADX | 38.83 |
| +DI | 13.01 |
| -DI | 34.91 |
| Chandelier Exit (Long, 3 ATRs) | 5.23 |
| Chandelier Exit (Short, 3 ATRs) | 5.18 |
| Upper Bollinger Bands | 6.50 |
| Lower Bollinger Band | 4.20 |
| Percent B (%b) | 0.19 |
| BandWidth | 42.91 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.46 |
| MACD Histogram | -0.0582 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.33 | ||||
| Resistance 3 (R3) | 5.28 | 5.00 | 5.21 | ||
| Resistance 2 (R2) | 5.00 | 4.82 | 5.02 | 5.17 | |
| Resistance 1 (R1) | 4.81 | 4.71 | 4.91 | 4.86 | 5.13 |
| Pivot Point | 4.53 | 4.53 | 4.58 | 4.56 | 4.53 |
| Support 1 (S1) | 4.35 | 4.35 | 4.44 | 4.40 | 4.13 |
| Support 2 (S2) | 4.07 | 4.24 | 4.09 | 4.09 | |
| Support 3 (S3) | 3.88 | 4.07 | 4.05 | ||
| Support 4 (S4) | 3.93 |
